Published May 25, 2016
Washington, DC—May 25, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Issue Panel 20—What Is the Value of Frameworks to Patients? The Case in Oncology—was held this morning in Washington, DC, USA. The moderator for the session was Josh Seidman, PhD, Senior Vice President, Avalere Health, Washington, DC, USA. Panelists included:
  • Rob Hauser, PhD, PharmD, Vice President, Cancer Treatment Centers of America, Boca Raton, FL, USA
  • Eric Kruep, MS, PharmD, Outcomes Research Liaison, Novartis Pharmaceuticals, East Hanover, NJ, USA
  • Frederick May, MD, Medical Director, Educators Mutual Insurance, Indianapolis, IN, USA
This Issue Panel explored the topic of value assessment frameworks and how these frameworks could foster shared decision making between care teams and patients. However, the panel stressed that in order to maximize utility, the frameworks need to provide the appropriate information that is meaningful to patients in making those decisions. Several tools have been made available over the past year that assess the clinical and economic impact of oncology drugs, including the American Society of Clinical Oncology and National Comprehensive Cancer Network assessment frameworks and Memorial Sloan-Kettering Cancer Center’s online assessment tool. The panel shared their early impressions of these tools, described the role these types of tools can play in shared decision making at the point of cancer care, addressed patient perspectives on value, and reviewed what evidence is needed to address gaps for provider and patient needs. Presentations and slide decks from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC.


Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now